Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

医学 二肽基肽酶-4抑制剂 安慰剂 药效学 药代动力学 2型糖尿病 内科学 体质指数 人口 2型糖尿病 糖尿病 二肽基肽酶-4 内分泌学 胃肠病学 药理学 替代医学 环境卫生 病理
作者
Carol Addy,Daniel Tatosian,Xiaoli S. Glasgow,Isaias Noel Gendrano,Eunkyung Kauh,Ashley Martucci,Amy O. Johnson‐Levonas,Diana Selverian,Catherine Matthews,Marie Gutierrez,John A. Wagner,S. Aubrey Stoch
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:38 (3): 516-530 被引量:25
标识
DOI:10.1016/j.clinthera.2015.12.020
摘要

Omarigliptin (MK-3102) is a potent, oral, long-acting dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan and in global development as a once-weekly treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) effects of omarigliptin in obese participants with and without T2DM.This was a Phase I, randomized, double-blind, placebo-controlled, multiple-dose study of 50-mg omarigliptin administered once weekly for 4 weeks. Participants included 24 obese but otherwise healthy subjects (panel A; omarigliptin, n = 18; placebo, n = 6) and 8 obese patients with T2DM (treatment naive, hemoglobin A1c ≥ 6.5% and ≤ 10.0% [panel B]; omarigliptin, n = 6; placebo, n = 2). Participants were 45 to 65 years of age with a body mass index of ≥ 30 and ≤ 40 kg/m(2). Blood sampling occurred at select time points, depending on the study panel, to evaluate the PK properties of omarigliptin, DPP-4 activity, active glucagon-like peptide 1 levels, and plasma glucose concentrations. Body weight was an exploratory end point. Due to sparse sampling in panel A, a thorough PK analysis was performed in obese patients with T2DM (panel B) only. PD analyses were performed in the overall study population (pooled panels A and B).PK profiles in obese participants with and without T2DM were similar to those observed in nonobese reference subjects (historical data). Steady state was achieved after 1 or 2 weekly doses in obese participants with and without T2DM. In obese patients with T2DM, omarigliptin was rapidly absorbed, with a median Tmax of 1 to 2.5 hours (days 1 and 22). Compared with those in reference subjects, the geometric mean ratios (95% CI) (Obese T2DM/reference) for steady-state plasma AUC0-168h, Cmax, and C168h were 0.80 (0.65-0.98), 0.86 (0.53-1.41), and 1.08 (0.88-1.33), respectively. Trough DPP-4 activity was inhibited by ~90%; postprandial (PP) 4-hour weighted mean active GLP-1 concentrations were increased ~2-fold; and PP glucose was significantly reduced with omarigliptin versus placebo in the pooled population. Omarigliptin was generally well-tolerated in the pooled population, and there were no hypoglycemic events. Consistent with other DPP-4 inhibitors, omarigliptin had no effect on body weight in this short-duration study.The administration of omarigliptin was generally well-tolerated in obese participants with and without T2DM, and the favorable PK and PD profiles support once-weekly dosing. Omarigliptin may provide an important once-weekly treatment option for patients with T2DM. ClinicalTrials.gov identifier: NCT01088711.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
目光之澄完成签到,获得积分10
刚刚
wanci应助研友_ndDPBn采纳,获得10
刚刚
耍酷的白梦完成签到,获得积分10
1秒前
miracle完成签到 ,获得积分10
2秒前
coding完成签到,获得积分10
3秒前
4秒前
犹豫水蓝完成签到,获得积分10
5秒前
yin完成签到,获得积分10
5秒前
JUGG完成签到,获得积分10
5秒前
CipherSage应助阿湫采纳,获得10
6秒前
FIN应助手机采纳,获得20
6秒前
星辰大海应助东黎采纳,获得10
6秒前
量子星尘发布了新的文献求助10
6秒前
wujingshuai完成签到,获得积分10
7秒前
少年完成签到,获得积分10
7秒前
星辰大海应助ficus_min采纳,获得10
8秒前
小柒柒完成签到,获得积分10
9秒前
sdfwsdfsd完成签到,获得积分10
10秒前
亮仔完成签到,获得积分10
11秒前
土豆丝发布了新的文献求助10
11秒前
ylw完成签到,获得积分20
12秒前
西门明雪完成签到,获得积分10
12秒前
12秒前
烟花应助万松辉采纳,获得10
13秒前
爆米花应助不站在雾里采纳,获得10
13秒前
yy完成签到,获得积分20
14秒前
高贵宛海完成签到,获得积分10
14秒前
854fycchjh完成签到,获得积分10
15秒前
16秒前
研友_ndDPBn发布了新的文献求助10
16秒前
番茄发布了新的文献求助30
16秒前
上官若男应助fw20210085采纳,获得10
17秒前
Aliensick发布了新的文献求助10
17秒前
sss2021完成签到,获得积分10
17秒前
丁一完成签到,获得积分10
17秒前
田様应助光能使者采纳,获得10
18秒前
19秒前
F123完成签到,获得积分10
19秒前
OnionJJ发布了新的文献求助10
19秒前
ccccchen完成签到,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048